TheDeveloping Countries Vaccine Manufacturers Network (DCVMN International) is a voluntary non-partisanpublic health alliance of health organizations and vaccine manufacturers. DCVMN aims to protect people globally against known and emerging infectious diseases through the provision of a consistent supply of high quality vaccines at affordable prices fordeveloping countries, to achievevaccine equity.[1][2][3] DCVMN includes many It was established in 2000[4]/2001,[5] and is headquartered in Switzerland.[4]
As of 2025, DCVMN International comprises over 48 public and private manufacturers across 17 countries and territories in Africa, Asia, Europe, the Middle East, and Latin America. During theCOVID-19 pandemic, DCVMN members supplied more than 60% of the global vaccine supply ofCOVID-19 vacccines, with 8 different vaccine technology platforms used to develop these vaccines between all of the 20 members that are engaging in the COVID-19 vaccine effort. DCVMN members reported that they had the capability to supply over 400 distinct vaccine products to 170 countries, more than 100 of these vaccines have WHO Prequalification, totalling more than 6 billion vaccine doses annually.[6]
The DCVMN is active in identifying obstacles in the processes of vaccine registration and use. It works to increase coordination of requirements and procedures to improve the prequalification, procurement and supply of vaccines. This can involve governments in different countries, theWorld Health Organization (WHO), andUnited Nations agencies such asUNICEF.[11][12][13]
DCVMN International is registered as a legal entity under Swiss jurisdiction, operating under Articles 60 and beyond of the Swiss Civil Code. While the DCVMN headquarters are anchored in Switzerland, the CEO's office is based in India.
^Jadhav, Suresh; Datla, Mahima; Kreeftenberg, Hans; Hendriks, Jan (20 March 2008). "The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries".Vaccine.26 (13):1611–1615.doi:10.1016/j.vaccine.2008.01.034.ISSN0264-410X.PMID18294742.
